Press release
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives from the pharmaceutical and biotech industries with innovative solution providers. At the event, Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer, presented her findings and experiences in striking a balanced medical review process to build a robust Pharmacovigilance strategy.
‘The talk generated a tremendous amount of interest in the topic and resulted in positive feedback and interesting discussions with delegates’ says Dr Treichel. ‘We were particularly pleased about specific requests that were made by trial sponsors at the event. Our Pharmacovigilance and Medical Review teams are very happy to provide this special service and therefore meet the growing demand of pharmaceutical and biotech companies.’
Most Pharmacovigilance systems suffer either from a complete lack of medical review integration or, at the other extreme, a single all-inclusive process resulting in over-integration. By adapting a balanced medical review process ICRC-Weyer is able to build a robust Pharmacovigilance strategy.
Dr Treichel’s talk featured several aspects of this topic, including the assessment of current risk management approaches to pinpoint drawbacks and improve Pharmacovigilance strategies, the identification of expected benefits, potential difficulties and practical considerations of medical review for effective integration, examining past case studies to uncover unforeseen threats and debunk false risks as well as improving processes and minimising overall risks through the successful execution of integrated medical review.
The presentation can be accessed via ICRC-Weyer’s website.
About ICRC-Weyer:
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.
ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.
Dr. Ulrike Treichel
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: Ulrike.Treichel@icrc-weyer.com
www.icrc-weyer.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ICRC-Weyer To Enhance Pharmacovigilance Risk Management here
News-ID: 248405 • Views: …
More Releases from ICRC-Weyer GmbH
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors.
An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.
‘A large…
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio.
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted…
More Releases for Weyer
Global Neonatal Incubator Market - AHT, Natus Medical, Weyer GmbH, Fanem
The report that is written on the title Neonatal Incubator Market covers all across the globe, recently added to the repository of Market Research, is titled ‘Global Neonatal Incubator Market 2017’. The research report analyses the historical as well as present performance of the worldwide Neonatal Incubator industry, and makes predictions on the future status of Neonatal Incubator market on the basis of this analysis.
An infant incubator is a…
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio.
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted…
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in…
New Medical Coding Procedures At Clinical CRO ICRC-Weyer
ICRC-Weyer GmbH has announced an enhancement to their medical coding procedures for drug development processes.
Until recently, the company had been utilizing limited licenses for the coding dictionary of the World Health Organization WHO (WHO DD/WHO Drug). WHO DD is an international classification of medicines created by the WHO Programme for International Drug Monitoring and managed by the Uppsala Monitoring Centre. It is used by pharmaceutical companies, clinical trial organizations…
